[Viewpoint] Precision medical mergers and acquisitions into a major trend in the next two or three years

From January 30, 2015, Obama proposed the American Precision Medicine Program, and the major track of precision medicine is almost occupied by startup companies. Of course, listed companies will not miss the dividend of precision medicine . In addition to participating in startups, mergers and acquisitions are another major way for listed companies to get involved in precision medicine.

"The combination of the medical field and precision medicine, for the listed company, in view of the precise medical treatment is still in the embryonic stage, the merger is more convenient, the foot is inserted first, but in the end it can be more difficult to judge." The rich fund "medicine one brother" Zhou Rui said in an interview with the reporter at the recent Bio4P, 2016 Precision Medical Innovation Forum.

"In the next two or three years, there will be many mergers and acquisitions in the field of precision medicine." Zhou Rui said. Today, the author will come to sort out the M&A cases and characteristics that appear in the field of precision medicine.

Small company R&D + big company mergers and acquisitions into mainstream mode

In 2016, the case of mergers and acquisitions in the field of precision medicine was no more than Berry and Kang's backdoor Tianxing instrument landing A shares, and is currently awaiting review. On the evening of August 29, Tianxing Instrument, which suspended trading for two and a half months, disclosed the announcement of the progress of major asset restructuring, and planned to sell all the assets, liabilities, business, personnel and other stock assets currently owned by it to Chengdu Tianxing Instrument (Group) Co., Ltd. Or its designated third party. At the same time, it issued shares to all shareholders of Berry and Kang to purchase 100% of its shares in Berry and Kang.

Berry and Kang, which was established six years ago, took the lead in marketization of non-invasive prenatal genetic testing from the beginning of its establishment. In 2011, it won a total of $17.8 million in the A-round financing of Junlian Capital, and in the middle of 2013, it won another 25 million. The B round of financing of the US dollar was led by Qiming Venture Capital. Subsequently, Berry seized the opportunity of the commercialization of non-invasive prenatal genetic testing from 2014 to 2015, and became another leader after the non-invasive prenatal genetic testing field. In 2016, Berry's new development was to borrow A-shares from A shares.

In the future, from a global perspective, “small company R&D + big company mergers and acquisitions” will become the mainstream business model for precision medicine.

On May 31, 2016, the media reported that Irish biopharmaceutical company Jazz Pharmaceuticals (JAZZ) will acquire Celator Pharmaceuticals (CPXX) for US$1.5 billion, which is about twice the market value of Celator Pharmaceuticals. Celator Pharmaceuticals is a well-deserved star of US stocks in 2016. The company announced after the suspension on March 14 that the company's new drug VYXEOS has been clinically proven to improve the overall survival rate of patients with high risk of acute myeloid leukemia (AML) (secondary). The company resumed trading the next day, and its stock price soared 400% in a single day and then continued to rise. The closing price as of May 31 was $17.53. The three-month increase has been close to 10 times, leading the entire Nasdaq market.

Mini Centrifuge

Mini Centrifuge,Laboratory Mini Centrifuge,Centrifuge Machine For Lab,Samll Centrifuge Machine

Guangdong Widinlsa International Co.Ltd , https://www.guangdongwidinlsa.com